We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
BIO-RAD LABORATORIES

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Autoantibody Status Guides Treatment in Myasthenia Gravis

By LabMedica International staff writers
Posted on 20 Dec 2023

Autoantibody status plays a significant role in diagnosis and therapy decisions for myasthenia gravis (MG), an immune-mediated neuromuscular junction disorder. The key serological markers in MG are antibodies against nicotinic acetylcholine receptors (AChR), which are found in about 85% of cases, and antibodies against muscle-specific kinase (MuSK), which are observed in approximately 6% of cases, the majority of which are anti-AChR negative. 15% of MG cases are seronegative. The antibody-mediated processes in MG result in the loss of functional AChR at the motor endplate, either through direct blocking, antigen modulation, or complement-mediated damage of the muscle membranes. Anti-AChR antibodies belong to the IgG1 subclass and can activate the complement cascade. In AChR antibody-positive cases, complement-inhibiting drugs are among the recommended therapies. On the other hand, anti-MuSK antibodies belong to the non-complement binding IgG4 subclass, as a result of which complement inhibitors are ineffective for this form. Hence, therapy selection should consider the autoantibody status along with disease activity, thymus pathology, and the patient’s age.

Currently, the gold standard for detection of anti-AChR and MuSK antibodies is radioimmunoprecipitation assay (RIPA) although it comes with a disadvantage of the need for radioactive reagents. Cell-based indirect immunofluorescence assays (CBAs) offer a viable alternative that is easier to implement. EUROIMMUN (Lübeck, Germany) has developed CBAs based on transfected human cell lines expressing the corresponding target antigens AChR (adult: AChR-E and fetal: AChR-G) and MuSK. In an evaluation study published in the Journal of the Neurological Sciences, the EUROIMMUN Anti-AChR CBA demonstrated similarly excellent specificity and a significantly higher sensitivity for MG compared to RIPA, detecting anti-AChR in 21% of patients otherwise considered to be seronegative.

In a further analysis, the Anti-AChR and Anti-MuSK CBAs demonstrated high positive and 100% negative agreement with RIPA in patients with clinically confirmed MG. CBAs thus provide equivalent or superior performance to RIPA without the use of radioactive materials. Moreover, anti-AChR and anti-MuSK antibodies can be analyzed simultaneously using the EUROIMMUN Myasthenia gravis Mosaic 2, which provides a composite of CBAs for adult/fetal AChR and MuSK together with a control substrate. This test is currently the only commercially available multiparameter assay for anti-AChR and anti-MuSK. The CBAs are CE-marked. The CBA procedure is simple and can be performed in any laboratory familiar with indirect immunofluorescence. There are automation options available to aid the processing and evaluation, allowing for the assay’s smooth integration into laboratory routines.

Related Links:
EUROIMMUN

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.